Svenska
MENUMENU

IMMray™ PanCan-d

Early detection of pancreatic cancer for increased survival rates

IMMrayTM PanCan-d is a unique blood test for the early detection of pancreatic cancer that has the potential to dramatically increase patient survival rates: from 5-8% to up to 49%. Our retrospective studies show that the test is able to detect stage I and stage II pancreatic cancer with an accuracy of 96%. A test with such a high level of accuracy would give clinicians a much greater chance of finding the cancer when it is still resectable by surgical procedures.

Click on image below for larger size.

Workflow

A standard patient blood sample is taken by the clinician and sent to the laboratory. At the laboratory, patient serum samples are applied on to the IMMray PanCan-d microarray that has room for up to 14 patient samples. Each microarray generates a biomarker signature that is evaluated for pancreatic cancer using advanced bioinformatics and complex software algorithms, after scanning with a standard fluorescent scanner.

IMMray PanCan-d has the potential to address several unmet clinical needs:

  1. Screening of high-risk groups i.e. familial/hereditary pancreatic cancer
  2. Testing of new onset diabetes type II patients over 50 years who suffer a 6-8 times increased risk of developing pancreatic cancer within 1-3 years
  3. Testing of patients with vague symptom profiles were the clinicans suspects, or wants to rule out, pancreatic cancer

IMMray PanCan-d is currently undergoing a prospective validation study to confirm our findings before market introduction. We are very interested in getting into contact with high-risk individuals with hereditary pancreatic cancer in the family.

References:

  1. Pancreatic registry in Japan – 20 years of experience, 2004.
  2. Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
  3. Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
  4. Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
  5. Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
  6. Mellby et al. A serum biomarker signature based-liquid biopsy for diagnosis of early stage pancreatic cancer. Manuscript submitted March 2018.
Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports